Bellicum Pharmaceuticals Inc  

(Public, NASDAQ:BLCM)   Watch this stock  
Find more results for Kevin D Huber´┐Ż
+0.13 (0.83%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.42 - 16.04
52 week 7.24 - 23.84
Open 15.64
Vol / Avg. 256,379.00/385,489.00
Mkt cap 412.04M
P/E     -
Div/yield     -
EPS -2.11
Shares 26.98M
Beta     -
Inst. own 60%
Aug 11, 2016
Q2 2016 Bellicum Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 16, 2016
Bellicum Pharmaceuticals Inc Annual Shareholders Meeting
Jun 16, 2016
Bellicum Pharmaceuticals Inc Annual Shareholders Meeting (Estimated)
Jun 8, 2016
Bellicum Pharmaceuticals Inc at Jefferies Healthcare Conference - Webcast
May 12, 2016
Bellicum Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 9, 2016
Q1 2016 Bellicum Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -16385.87% -17215.60%
Operating margin -16500.00% -17423.76%
EBITD margin - -16998.23%
Return on average assets -37.33% -27.26%
Return on average equity -41.36% -28.25%
Employees 72 -
CDP Score - -


2130 W Holcombe Blvd Ste 800
HOUSTON, TX 77030-3307
United States - Map
+1-832-3841100 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. BPX-501 is an adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation. The Company's CID-based technologies include CaspaCIDe, CIDeCAR and GoCAR-T.

Officers and directors

James Farrell Brown Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Thomas J. Farrell President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Alan A. Musso CPA Chief Financial Officer, Treasurer
Age: 53
Bio & Compensation  - Reuters
Annemarie B. Moseley M.D. Ph.D. Chief Operating Officer, Senior Vice President - Clinical Development and Regulatory Affairs
Age: 60
Bio & Compensation  - Reuters
Ken Moseley J.D. Senior Vice President, General Counsel
Age: 58
Bio & Compensation  - Reuters
Peter L. Hoang Senior Vice President - Business Development and Strategy
Age: 43
Bio & Compensation  - Reuters
Kevin M. Slawin M.D. Chief Medical Officer, Chief Technology Officer, Director
Age: 54
Bio & Compensation  - Reuters
David M. Spencer Ph.D. Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Joseph Senesac Vice President - Manufacturing
Age: 44
Bio & Compensation  - Reuters
Jim Daly Director
Bio & Compensation  - Reuters